Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT01597713 | A Trial Investigating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of NNC0148-0000-0362 in Healthy Subjects | PHASE1 | COMPLETED | 83 | — | — | May 1, 2012 | Oct 1, 2012 | May 29, 2015 | 1 | Germany |
| Arm | Type | Description |
|---|---|---|
| Part 1, level 1-7 escalating doses | EXPERIMENTAL | - |
| Part 2, cross-over | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| NNC 0148-0000-0362 | DRUG | Subjects will be randomised to receive a single dose of NNC 0148-0000-0362 orally within each dose group |
| insulin glargine | DRUG | As an active comparator, one standard dose will be given subcutaneously (s.c., under the skin) within each dose group |
| placebo | DRUG | Subjects will receive a single dose of oral placebo within each dose group |
Inclusion Criteria: * Body mass index 18-28 kg/m\^2 (both inclusive) * Subject who is considered to be healthy based on the medical history, physical examination, and the results of vital signs, electrocardiogram (ECG) and clinical laboratory tests performed during the screening visit, as judged by...